Novartis' Afinito Significantly Improves Progression-Free Survival In Advanced Nonfunctional GI and Lung NET

by Benzinga Staff
September 27, 2015 6:48 AM | 28 seconds read | Make a Comment

27% profit every 20 days?

This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.

Novartis (NYSE: NVS) announced Saturday, results of a Phase III pivotal study showing Afinitor® (everolimus) tablets reduced the risk of progression by 52% (hazard ratio [HR] = 0.48; 95% confidence interval [CI], 0.35-0.67; p<0.00001) 2015 vs placebo in patients with advanced, progressive, nonfunctional neuroendocrine tumors (net) of gastrointestinal (gi) or lung origin. the study, radiant-4, will be presented at european cancer congress (ecc) vienna, austria, and was highlighted ecc press conference on saturday, september 26[1]. additionally, data show everolimus, a mammalian target rapamycin (mtor) inhibitor, extended median

ENTER TO WIN $500 IN STOCK OR CRYPTO

Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!

See full press release

27% profit every 20 days?

This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.

Posted In: NewsContractsPress Releases

© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.